|[October 28, 2013]
Pulmatrix Announces Positive Results from Initial Stage of Phase IB Clinical Study of PUR0200 in COPD Patients
LEXINGTON, Mass. --(Business Wire)--
Pulmatrix today announced the successful completion and positive results
of the first part of a two-part Phase IB clinical study in chronic
obstructive pulmonary disease (COPD) patients with their lead clinical
candidate PUR0200. PUR0200 is a bronchodilator therapy for COPD and is
the first small molecule product from the company's novel iSPERSE™
inhaled dry powder technology. The first part of the Phase 1B clinical
trial evaluated the safety, tolerability and the
pharmacokinetic/pharmacodynamic profile of single ascending doses of
PUR0200 in patients with moderate COPD.
The first part of the Phase 1B study evaluated pharmacokinetics and
pulmonary function after administration of four single ascending doses
of PUR0200 in 24 patients with moderate COPD. All doses of PUR0200 were
generally well tolerated and were associated with increases in lung
function, as measured by peak and trough forced expiratory volume (FEV1)
from baseline, and compared to placebo dosing. Pharmacokinetic
assessments affirmed the effective lung delivery of PUR0200 and the
iSPERSE platform and compared favorably to published data on lactose
blend formulations. The data from the first part of the study will be
used to inform dose selection for the second part of the study, a
cross-over design study that starts this month and includes an active
comparator arm. The study is targeted for completion in Q1 2014 and data
from both parts of the study will be presented at a future scientific
David Hava, PhD, Chief Scientific Officer of Pulmatrix, commented, "The
data from the first part of our PUR0200 clinical trial mark a
ignificant milestone for our lead iSPERSE drug candidate. This clinical
evidence validates that iSPERSE offers exceptional lung delivery
advantages relative to existing products. These data significantly
advance our platform and provide impetus for continued development of
PUR0200 and other products in our pipeline."
The Phase 1B study is being conducted by Quotient Clinical in
Nottingham, England, in conjunction with Professor Dave Singh at the
Medicines Evaluation Unit in Manchester, England and PUR0200 is being
manufactured by Quotient Clinical for the study.
Robert Clarke, PhD, Chief Executive Officer of Pulmatrix added, "These
study results with PUR0200 represent an important step in establishing a
next generation approach for creating easily inhaled, easy-to-use
therapeutics with the iSPERSE technology. We are encouraged by the
continued robust performance of PUR0200 in COPD patients and look
forward to completion of the clinical trial in early 2014."
PUR0200 was designed using the Pulmatrix proprietary iSPERSE particle
engineering platform, an engineered particle technology that facilitates
flow rate independent, high efficiency drug delivery to the lungs. The
PUR0200 bronchodilator therapy is designed to provide improved
performance over current therapeutics on the market.
Chronic obstructive pulmonary disease (COPD) is a major cause of death
and disability throughout the world. The World Health Organization (WHO)
figures estimated that 210 million people are living with COPD.
According to WHO more than 3 million people died of COPD in 2005, which
corresponds to 5% of all deaths globally. WHO predicts that COPD will
become the third leading cause of death worldwide by 2030.
As COPD progresses, lung function declines and physical activity may
become severely limited, adversely affecting the quality of patients'
lives. Early diagnosis and intervention with appropriate treatment
following an exacerbation is important to help patients recover more
rapidly and improve their quality of life.
Pulmatrix, Inc. is a clinical stage biotechnology company developing and
commercializing a novel inhaled dry powder drug platform to create a new
generation of inhaled therapeutics. The platform, called iSPERSE™
(inhaled small particles easily respirable and emitted), enables drugs
to be delivered in inhaled dry powders with unique properties for high
drug loading and highly efficient dispersibility and delivery to the
airways. iSPERSE can create dry powder formulations with virtually any
drug substance, including small molecules, biologics and multi-drug
The Company is pursuing both proprietary and partnered applications for
iSPERSE. For additional information about Pulmatrix, please visit www.pulmatrix.com.
iSPERSE™ is a trademark of Pulmatrix, Inc.
[ Back To Technology News's Homepage ]